NervGen Pharma (TSXV:NGEN) Buildings And Improvements : C$0.00 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Buildings And Improvements?

NervGen Pharma Buildings And Improvements Historical Data

The historical data trend for NervGen Pharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Buildings And Improvements Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

Get a 7-Day Free Trial

NervGen Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

NervGen Pharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

NervGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

NGENF:USA 9UA:Germany

Address

112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4

Website

https://www.nervgen.com

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Executives

John Ruffolo	Director
Krista Mckerracher	Director
William Joseph Radvak	Director
Harold Punnett	10% Security Holder, Director
Robert Pilz	Senior Officer

NervGen Pharma Headlines

No Headlines